31 unknown, 17 completed, 17 recruiting, 11 not yet recruiting. 29 Phase 2, 17 Phase 3, 14 Not applicable, 4 Early Phase 1, 3 Phase 1.
Follow Neoadjuvant Chemotherapy: new trials by email Literature Review of Neoadjuvant Chemotherapy trials Research Report on Neoadjuvant Chemotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2026-09-15 | 2026-06-24 |
| Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy Neoadjuvant Chemotherapy, Partial cystectomy with Extended pelvic lymph node dissection, Adjuvant systemic therapy - Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma | Phase 2 | Withdrawn | Case Comprehensive Cancer Center | 2026-09-01 | 2026-09-24 | |
| GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer Neoadjuvant chemotherapy, Olanzapine - Gastric Adenocarcinoma, Gastric Cancer | Phase 2 | Not yet recruiting | University of Illinois at Chicago | 26 | 2026-09-01 | 2026-08-21 |
| Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC. Stereotactic body radiotherapy (SBRT), neoadjuvant immunotherapy, Neoadjuvant Chemotherapy - Non Small Cell Lung Cancer, Stereotactic Body Radiotherapy | Phase 3 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 201 | 2026-05-01 | 2026-05-29 |
| Targeting Stress-Driven Inflammatory and Angiogenic Pathways With Brief ACT to Enhance Neoadjuvant Chemotherapy Response in Locally Advanced Breast Cancer Brief Acceptance and Commitment Therapy, Standard Counseling, Neoadjuvant Chemotherapy - Breast Cancer, Breast Neoplasm Female | Not applicable | Not yet recruiting | Universitas Airlangga | 54 | 2026-04-28 | 2026-05-06 |
| Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial ctDNA-Based Molecular Residual Disease (MRD) Monitoring and Immunoscore Assessment, Neoadjuvant Chemotherapy, Adjuvant chemotherapy - Minimal Residual Disease, Immunoscore | Not applicable | Not yet recruiting | Sun Yat-sen University | 100 | 2026-02-24 | 2026-02-17 |
| Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08) Neoadjuvant therapy combined with Trastuzumab Rezetecan and Toripalimab, Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy - HR Positive/HER2 Low Breast Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 111 | 2026-02-01 | 2026-02-03 |
| Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy Neoadjuvant Chemotherapy, Radical Cystectomy - Muscle Invasive Bladder Cancer | Not applicable | Recruiting | Assiut University | 76 | 2025-09-01 | 2025-10-02 |
| Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer Neoadjuvant chemotherapy, Upfront Surgery Group - Pancreas Cancer, Periampullary Cancer | Phase 3 | Recruiting | Minia University | 262 | 2025-07-20 | 2026-09-11 |
| Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer Stereotactic Body Radiation Therapy (SBRT), Toripalimab, Neoadjuvant Chemotherapy - Breast Cancer | Phase 2 | Recruiting | Xijing Hospital | 27 | 2025-06-05 | 2026-08-14 |
| Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer Sintilimab, Short-course radiotherapy, Long-course concurrent chemoradiotherapy - Locally Advanced Rectal Cancer (LARC) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 228 | 2025-06-01 | 2025-06-26 |
| Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell Carcinoma of the External Auditory Canal Tislelizumab - Squamous Cell Carcinoma of External Auditory Canal, Locally Advanced Tumor | Phase 2 | Recruiting | Eye & ENT Hospital of Fudan University | 50 | 2025-05-12 | 2026-01-27 |
| Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy Neoadjuvant therapy with PD-L1 inhibitor - Esophageal Cancer | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 600 | 2025-04-01 | 2025-03-21 | |
| Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04) Neoadjuvant Chemotherapy in Combination with Toripalimab, Neoadjuvant Chemotherapy - HR+/HER2- Breast Cancer | Phase 3 | Recruiting | First Affiliated Hospital of Zhejiang University | 194 | 2025-03-24 | 2025-05-18 |
| Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC Neoadjuvant Chemotherapy, Immunotherapy, Radical surgery - Cervical Cancers | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 35 | 2025-03-15 | 2025-04-01 |
| Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB) neoadjuvant chemotherapy, curative surgery - Gall Bladder Carcinoma | Phase 3 | Recruiting | Rajiv Gandhi Cancer Institute & Research Center, India | 114 | 2025-01-01 | 2025-04-16 |
| Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC Neoadjuvant immunotherapy combined with chemotherapy, Neoadjuvant chemotherapy - Lung Cancer (NSCLC) | Unknown | Capital Medical University | 20 | 2024-09-25 | 2024-09-25 | |
| Use of Machine Learning Techniques for Serial Assessment of Systemic Inflammatory Markers in Breast Cancer Patients Surgery (Mastectomy or quadrantectomy) - Breast Cancer | Enrolling by invitation | Federal University of São Paulo | 4500 | 2024-08-01 | 2025-03-12 | |
| Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer Intermittent Fasting, Neoadjuvant chemotherapy - Epithelial Ovarian Cancer | Not applicable | Recruiting | Case Comprehensive Cancer Center | 20 | 2024-07-11 | 2026-08-06 |
| Aromatherapy in the Treatment of Early Breast Cancer neoadjuvant chemotherapy, aromatherapy - Early Breast Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2024-07-01 | 2024-07-09 |
Showing 20 of 85. Sign in to see all of them.
Breast Neoplasms (20) · Colonic Neoplasms (5) · Fallopian Tube Neoplasms (5) · Stomach Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Ovarian Epithelial (4) · Uterine Cervical Neoplasms (4) · Esophageal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Ovarian Neoplasms (3) · Pancreatic Neoplasms (3) · Rectal Neoplasms (3) · Urinary Bladder Neoplasms (3) · Cholangiocarcinoma (2) · Neoplasms (2)
Assiut University (3) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3) · Asan Medical Center (2) · Case Comprehensive Cancer Center (2) · Chinese Academy of Medical Sciences (2) · Chinese Academy of Sciences (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · First Affiliated Hospital of Zhejiang University (2) · Fudan University (2) · Minia University (2) · Shanghai Gynecologic Oncology Group (2) · Sun Yat-sen University (2) · The First Affiliated Hospital with Nanjing Medical University (2) · Xijing Hospital (2)
China (39) · United States (11) · Egypt (5) · France (5) · South Korea (5) · Canada (4) · Spain (4) · India (3) · Italy (3) · Belgium (2) · Denmark (2) · Japan (2) · Netherlands (2) · United Kingdom (2) · Argentina (1)
Afonso C Nazario, PhD (1) · Alessandro Colombo, MD (1) · Amal R Ibrahim, Ass.Prof (1) · Amr Darwish, Lecturer (1) · Asdi Wihandono, MD, Surgical Oncologist (1) · Aslam Ejaz, MD (1) · Bong-Hyeon Kye, MD.PhD. (1) · Charles Cunningham, PhD (1) · Christopher G. Tretter, M.D. (1) · Dimitri Christoforidis (1) · Elena Gabriela Chiorean, M.D. (1) · Fabienne Valentin, MD (1) · Fabio Landoni, MD (1) · Feng Jiang, M.D. (1) · Fernando Cabanillas, MD (1)
PMID 11813623, PMID 14530720, PMID 18026089, PMID 18320278, PMID 19770374, PMID 20857337, PMID 21084184, PMID 21296855, PMID 21444866, PMID 21684205, PMID 22189383, PMID 22552194, PMID 22610353, PMID 23242673, PMID 24211053, PMID 24266955, PMID 24373477, PMID 24493117, PMID 24847029, PMID 24876941, PMID 24982463, PMID 25038015, PMID 25180663, PMID 25249141, PMID 25691613, PMID 26254683, PMID 26808342, PMID 28131785, PMID 28659128, PMID 29403496, PMID 30686350, PMID 31553463, PMID 32528099, PMID 32637899, PMID 33538338, PMID 33729467, PMID 34782748, PMID 34899751, PMID 35912196, PMID 36059450, PMID 36059520, PMID 36400384, PMID 37655106, PMID 37656948, PMID 38086314, PMID 38342430, PMID 38479803, PMID 39020518, PMID 39097916, PMID 39276114
2008 (1)